Survivin blockade sensitizes rhabdomyosarcoma cells for lysis by fetal acetylcholine receptor-redirected T cells

American Journal of Pathology

Volumn 182, Issue 6, 2013, Pages 2121-2131

  Simon Keller, Katja ^a   Paschen, Annette ^b   Hombach, Andreas A ^c   Ströbel, Philipp ^d   Coindre, Jean Michel ^e   Eichmüller, Stefan B ^f   Vincent, Angela ^g   Gattenlöhner, Stefan ^h   Hoppe, Florian ⁱ   Leuschner, Ivo ^j   Stegmaier, Sabine ^k   Koscielniak, Ewa ^k   Leverkus, Martin ^a   Altieri, Dario C ^l   Abken, Hinrich ^c   Marx, Alexander ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^e INSTITUT BERGONIÉ   (France)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h JUSTUS LIEBIG UNIVERSITY   (Germany)

ⁱ KLINIKUM OLDENBURG   (Germany)

^j UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^k OLGAHOSPITAL   (Germany)

^l WISTAR INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CHOLINERGIC RECEPTOR; INDUCIBLE T CELL COSTIMULATOR LIGAND; INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN INHIBITOR; SHEPHERDIN; SMALL INTERFERING RNA; SURVIVIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; CANCER CELL; CANCER INHIBITION; CASE REPORT; CHILD; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHABDOMYOSARCOMA; T LYMPHOCYTE; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; BIOPSY; CHILD, PRESCHOOL; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INDUCIBLE T-CELL CO-STIMULATOR LIGAND; INFANT; INHIBITOR OF APOPTOSIS PROTEINS; LIGANDS; MALE; MICE; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; RECEPTORS, CHOLINERGIC; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878258717     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.02.017     Document Type: Article

References (50)

1. T.M. Dantonello, C. Int-Veen, D. Harms, I. Leuschner, B.F. Schmidt, M. Herbst, H. Juergens, H.G. Scheel-Walter, S.S. Bielack, T. Klingebiel, R. Dickerhoff, S. Kirsch, I. Brecht, R. Schmelzle, M. Greulich, H. Gadner, J. Greiner, I. Marky, J. Treuner, and E. Koscielniak Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults J Clin Oncol 27 2009 1446 1455
2. M. Wachtel, and B.W. Schäfer Targets for cancer therapy in childhood sarcomas Cancer Treat Rev 36 2010 318 327
3. C.L. Mackall, E.H. Rhee, E.J. Read, H.M. Khuu, S.F. Leitman, D. Bernstein, M. Tesso, L.M. Long, D. Grindler, M. Merino, W. Kopp, M. Tsokos, J.A. Berzofsky, and L.J. Helman A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas Clin Cancer Res 14 2008 4850 4858
4. Y. Hashii, E. Sato, H. Ohta, Y. Oka, H. Sugiyama, and K. Ozono WT1 peptide immunotherapy for cancer in children and young adults Pediatr Blood Cancer 55 2010 352 355
5. Z. Eshhar The T-body approach: redirecting T cells with antibody specificity Y. Chernajovsky, A. Nissim, Therapeutic Antibodies 2008 Springer Berlin Heidelberg 329 342
6. I. Mellman, G. Coukos, and G. Dranoff Cancer immunotherapy comes of age Nature 480 2011 480 489
7. K. Zuberek, V. Ling, P. Wu, H.L. Ma, J.P. Leonard, M. Collins, and K. Dunussi-Joannopoulos Comparable in vivo efficacy of CD28/B7, ICOS/GL50, and ICOS/GL50B costimulatory pathways in murine tumor models: IFNγ-dependent enhancement of CTL priming, effector functions, and tumor specific memory CTL Cell Immunol 225 2003 53 63
8. X. Liu, X.F. Bai, J. Wen, J.X. Gao, J. Liu, P. Lu, Y. Wang, P. Zheng, and Y. Liu B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD(8)+ T lymphocytes in vivo J Exp Med 194 2001 1339 1348
9. M.F. Krummel, W.R. Heath, and J. Allison Differential coupling of second signals for cytotoxicity and proliferation in CD8+ T cell effectors: amplification of the lytic potential by B7 J Immunol 163 1999 2999 3006
10. M. Chmielewski, A.A. Hombach, and H. Abken CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack Gene Ther 18 2011 62 72
11. A. Hombach, A. Wieczarkowiecz, T. Marquardt, C. Heuser, L. Usai, C. Pohl, B. Seliger, and H. Abken Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule J Immunol 167 2001 6123 6131
12. J.N. Kochenderfer, M.E. Dudley, S.A. Feldman, W.H. Wilson, D.E. Spaner, I. Maric, M. Stetler-Stevenson, G.Q. Phan, M.S. Hughes, R.M. Sherry, J.C. Yang, U.S. Kammula, L. Devillier, R. Carpenter, D.A. Nathan, R.A. Morgan, C. Laurencot, and S.A. Rosenberg B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells Blood 119 2012 2709 2720
13. S. Gattenloehner, A. Vincent, I. Leuschner, S. Tzartos, H. Muller-Hermelink, T. Kirchner, and A. Marx The fetal form of the acetylcholine receptor distinguishes rhabdomyosarcomas from other childhood tumors Am J Pathol 152 1998 437 444
14. S. Gattenlöhner, A. Marx, B. Markfort, S. Pscherer, S. Landmeier, H. Juergens, H.K. Müller-Hermelink, I. Matthews, D. Beeson, A. Vincent, and C. Rossig Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor Cancer Res 66 2006 24 28
15. S. Gattenlöhner, H.-K. Müller-Hermelink, and A. Marx Polymerase chain reaction-based diagnosis of rhabdomyosarcomas: comparison of fetal type acetylcholine receptor subunits and myogenin Diagn Mol Pathol 7 1998 129 134
16. S. Gattenloehner, B. Dockhorn-Dworniczak, I. Leuschner, A. Vincent, H. Müller-Hermelink, and A. Marx A comparison of MyoD1 and fetal acetylcholine receptor expression in childhood tumors and normal tissues implications for the molecular diagnosis of minimal disease in rhabdomyosarcomas J Mol Diagn 1 1999 23 31
17. K. Simon-Keller, S. Barth, A. Vincent, and A. Marx Targeting the fetal acetylcholine receptor in rhabdomyosarcoma Expert Opin Ther Targets 17 2013 127 138
18. H. Kashkar, J.-M. Seeger, A. Hombach, A. Deggerich, B. Yazdanpanah, O. Utermohlen, G. Heimlich, H. Abken, and M. Kronke XIAP targeting sensitizes Hodgkin lymphoma cells for cytolytic T-cell attack Blood 108 2006 3434 3440
19. J.M. Seeger, P. Schmidt, K. Brinkmann, A.A. Hombach, O. Coutelle, P. Zigrino, D. Wagner-Stippich, C. Mauch, H. Abken, M. Krönke, and H. Kashkar The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack Cancer Res 70 2010 1825 1834
20. D. Hu, S. Liu, L. Shi, C. Li, L. Wu, and Z. Fan Cleavage of survivin by Ganzyme M triggers degradation of the survivin-X-linked inhibitor of apoptosis protein (XIAP) complex to free caspase activity leading to cytolysis of target tumor cells J Biol Chem 285 2010 18326 18335
21. D. Altieri Survivin and IAP proteins in cell-death mechanisms Biochem J 430 2010 199 205
22. A. Hombach, C. Schneider, D. Sent, D. Koch, R.A. Willemsen, V. Diehl, W. Kruis, R.L. Bolhuis, C. Pohl, and H. Abken An entirely humanized CD3 ζ-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells Int Cancer 88 2000 115 120
23. T.M. Dantonello, C. Int-Veen, P. Winkler, I. Leuschner, A. Schuck, B.F. Schmidt, H. Lochbuehler, S. Kirsch, E. Hallmen, I. Veit-Friedrich, S.S. Bielack, F. Niggli, B. Kazanowska, R. Ladenstein, T. Wiebe, T. Klingebiel, J. Treuner, and E. Koscielniak Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma J Clin Oncol 26 2008 406 413
24. S. Stegmaier, C. Poremba, K.-L. Schaefer, I. Leuschner, B. Kazanowska, A.N. Békássy, S.S. Bielack, T. Klingebiel, and E. Koscielniak Prognostic value of PAX-FKHR fusion status in alveolar rhabdomyosarcoma: a report from the cooperative soft tissue sarcoma study group (CWS) Pediatr Blood Cancer 57 2011 406 414
25. M.R. Stratton, B.R. Reeves, and C.S. Cooper Misidentified cell Nature 337 1989 311 312
26. A. Hombach, C. Heuser, and H. Abken Generation, expression, and monitoring of recombinant immune receptors for use in cellular immunotherapy Methods Mol Biol 207 2003 365 381
27. M. Carli, R. Colombatti, O. Oberlin, G. Bisogno, J. Treuner, E. Koscielniak, G. Tridello, A. Garaventa, R. Pinkerton, and M. Stevens European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors J Clin Oncol 22 2004 4787 4794
28. J. Plescia, W. Salz, F. Xia, M. Pennati, N. Zaffaroni, M.G. Daidone, M. Meli, T. Dohi, P. Fortugno, Y. Nefedova, D.I. Gabrilovich, G. Colombo, and D.C. Altieri Rational design of shepherdin, a novel anticancer agent Cancer Cell 7 2005 457 468
29. S. Kuçi, E. Rettinger, B. Voss, G. Weber, M. Stais, H. Kreyenberg, A. Willasch, Z. Kuçi, E. Koscielniak, S. Klöss, D. von Laer, T. Klingebiel, and P. Bader Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation Haematologica 95 2010 1579 1586
30. D. Cho, D.R. Shook, N. Shimasaki, Y.H. Chang, H. Fujisaki, and D. Campana Cytotoxicity of activated natural killer cells against pediatric solid tumors Clin Cancer Res 16 2010 3901 3909
31. H. Wiendl, M. Mitsdoerffer, D. Schneider, A. Melms, H. Lochmuller, R. Hohlfeld, and M. Weller Muscle fibres and cultured muscle cells express the B7.1/2 related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies Brain 126 2003 1026 1035
32. S. Fulda Exploiting apoptosis pathways for the treatment of pediatric cancers Pediatr Blood Cancer 53 2009 533 536
33. H. Caldas, M. Holloway, B. Hall, S. Qualman, and R. Altura Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo J Med Genet 43 2006 119 128
34. S. Singh, C. Vinson, C.M. Gurley, G.T. Nolen, M.L. Beggs, R. Nagarajan, E.F. Wagner, D.M. Parham, and C.A. Peterson Impaired Wnt signaling in embryonal rhabdomyosarcoma cells from p53/c-fos double mutant mice Am J Pathol 177 2010 2055 2066
35. K. Izeradjene, L. Douglas, A.B. Delaney, and J.A. Houghton Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex Cancer Res 64 2004 8036 8044
36. C. Margue, M. Bernasconi, F. Barr, and B. Schäfer Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR Oncogene 19 2000 2921 2929
37. L.H. Mayeenuddin, Y. Yu, Z. Kang, L.J. Helman, and L. Cao Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x(L) Oncogene 29 2010 6367 6377
38. C. Wei, S. Ball, L. Lin, A. Liu, J. Fuchs, P. Li, C. Li, and J. Lin Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells Int J Oncol 38 2011 279 285
39. H. Zhou, T. Shen, Y. Luo, L. Liu, W. Chen, B. Xu, X. Han, J. Pang, C. Rivera, and S. Huang The antitumor activity of the fungicide ciclopirox Int J Cancer 127 2010 2467 2477
40. F. Rödel, S. Reichert, T. Sprenger, U.S. Gaipl, J. Mirsch, T. Liersch, S. Fulda, and C. Rödel The role of survivin for radiation oncology: moving beyond apoptosis inhibition Curr Med Chem 18 2011 191 199
41. R.A. Carrasco, N.B. Stamm, E. Marcusson, G. Sandusky, P. Iversen, and B.K. Patel Antisense inhibition of survivin expression as a cancer therapeutic Mol Cancer Ther 10 2011 221 232
42. T. Dohi, K. Okada, F. Xia, C.E. Wilford, T. Samuel, K. Welsh, H. Marusawa, H. Zou, R. Armstrong, S. Matsuzawa, G.S. Salvesen, J.C. Reed, and D.C. Altieri An IAP-IAP complex inhibits apoptosis J Biol Chem 279 2004 34087 34090
43. S. Reed, H. Li, C. Li, and J. Lin Celecoxib inhibits STAT3 phosphorylation and suppresses cell migration and colony forming ability in rhabdomyosarcoma cells Biochem Biophys Res Commun 407 2011 450 455
44. K. Krysan, F.H. Merchant, L. Zhu, M. Dohadwala, J. Luo, Y. Lin, N. Heuze-Vourc'h, M. Põld, D. Seligson, D. Chia, L. Goodglick, H. Wang, R. Strieter, S. Sharma, and S. Dubinett COX-2-dependent stabilization of survivin in non-small cell lung cancer FASEB J 18 2004 206 208
45. S. Galban, and C.S. Duckett XIAP as a ubiquitin ligase in cellular signaling Cell Death Differ 17 2009 54 60
46. H. Kashkar, A. Deggerich, J.-M. Seeger, B. Yazdanpanah, K. Wiegmann, D. Haubert, C. Pongratz, and M. Kronke NF-{kappa}B-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs Blood 109 2007 3982 3988
47. S. Gattenlöhner, H. Jörissen, M. Huhn, A. Vincent, D. Beeson, S. Tzartos, A. Mamalaki, B. Etschmann, H.K. Muller-Hermelink, E. Koscielniak, S. Barth, and A. Marx A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model J Biomed Biotechnol 2010 2010 187621
48. M. Tanioka, H. Nokihara, N. Yamamoto, Y. Yamada, K. Yamada, Y. Goto, T. Fujimoto, R. Sekiguchi, K. Uenaka, S. Callies, and T. Tamura Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors Cancer Chemother Pharmacol 68 2011 505 511
49. A.W. Tolcher, A. Mita, L. Lewis, C.R. Garrett, E. Till, A.I. Daud, A. Patnaik, K. Papadopoulos, C. Takimoto, P. Bartels, A. Keating, and S. Antonia Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin J Clin Oncol 26 2008 5198 5203
50. D.C. Talbot, M. Ranson, J. Davies, M. Lahn, S. Callies, V. André, S. Kadam, M. Burgess, C. Slapak, A.L. Olsen, P.J. McHugh, J.S. de Bono, J. Matthews, A. Saleem, and P. Price Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose Study Clinical Cancer Res 16 2010 6150 6158